Maegim

Stock search

Search by company name, 6-digit code, or Korean initials (e.g. ㅅㅅㅈㅈ)

☆한국어

Alteogen Inc.

알테오젠196170KOSDAQSector: Pharma & Biotech
₩286,0000.87%Market cap ₩19.92TAs of Sep 7, 2026 close · updated once daily
Market cap
₩19.92T
#1 in KOSDAQ
141.8x
Sector median 15.7x (profitable cos.)
45.05x
Sector median 1.59x
0.1%
Sector median 0.0%
A
Grade A65.6 ptsTop 20% of 2,522 graded stocksMethodology v2.0
Financial strength
74.9/100
Growth momentum
94.5/100
Price attractiveness
32.8/100
Shareholder Return
76.0/100

As of Sep 7, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

How to read this grade
SACurrentBCDF

Toward S means a higher total-score band; toward F, a lower band. Badges are distinguished by ink intensity and shape (fill, outline, dashed) — never by hue.

Maegim maps a total score — built from sector-relative percentile scoring — onto fixed, predefined thresholds to assign one of six bands, S to F. This stock is scored by the same formula as all 2,522 graded stocks and is currently in band A with a total score of 65.6 points.

How grades are computed →What grades do and don’t mean →What the grade does not reflect →

Position within sector

Mechanically selected indicators in the top or bottom 30% of sector percentiles · among 250 stocks in Pharma & Biotech

1-year closing price

Loading closing price history…
 
Low ₩206,204High ₩430,105
Latest close
Price change by period
1W
6.90%
1M
6.20%
3M
11.70%
1Y
22.20%

Adjusted for 1 price-basis change(s) such as stock splits or reverse splits during the period.

As of the Sep 7, 2026 close · updated once daily · a factual record computed from closing prices only; dividends are not included, and this is not a buy or sell signal.

1

Financial strength

74.9/100
How much debt does it carry relative to equity?
53.8%
Sector median 51.6%
Sector lowhighBottom 49.6% in sector
Can it cover what's due within a year?
200.6%
Sector median 191.7%
Sector lowhighTop 47.6% in sector
How much of revenue becomes profit?
49.5%
Sector median -2.4%
Sector lowhighTop 0.6% in sector
How much did it earn on its own capital?
31.8%
Sector median -4.5%
Sector lowhighTop 1.8% in sector

Source filing: annual report (consolidated) — view original ↗

2

Growth momentum

94.5/100
How much did revenue grow in a year?
109.9%
Sector median 6.4%
Sector lowhighTop 8.4% in sector
Has it grown steadily over three years?
95.7%
Sector median 4.9%
Sector lowhighTop 5.8% in sector
Did core profits grow in a year?
320.8%
Sector median 3.6%
Sector lowhighTop 4.7% in sector
Are core profits higher than three years ago?
463.9%
Sector median 3.5%
Sector lowhighTop 3% in sector

Financial trend

Revenue

Growth & margin

Revenue growth Operating margin

Year over year — alongside the sector median

This stock Sector median

A factual chart of confirmed annual results from annual reports — the same source as the grading indicators. Not a buy or sell signal.

Source filing: annual report (consolidated) — view original ↗

3

Price attractiveness

32.8/100
Is the price expensive relative to earnings?
141.8x
Sector median P/E of profitable peers 15.7x · 58% loss-making
Sector lowhighTop 38.7% in sector
Is the price expensive relative to book value?
45.05x
Sector median 1.59x
Sector lowhighBottom 4.3% in sector

Valuation uses the Sep 7, 2026 close and market cap

4

Shareholder Return

Single-indicator axis76.0/100
Does the company actually pay dividends?
0.1%
Sector median 0.0%
Sector lowhighTop 24% in sector

Dividend per share (annual)

Cash dividend per common share as stated in annual reports. ₩0 means no dividend that year.

Dividends & treasury shares

Total cash dividends (FY2025)
₩20.0B
Cash payout ratio, consolidated (FY2025)
14.1%
Treasury shares (FY2023)
23,706 shares (0.0% of shares issued)

Source: annual report (DART) — dividend allocation & total shares

Source filing: annual report (consolidated) — view original ↗

Financial checklist

Based on the FY2025 annual report · year-over-year comparison · determined on Sep 7, 2026

Of 9 items: 6 met · 2 not met · 1 not computable

Not metMetNot computable

Positive net income
Whether net income (attributable to owners where available) is above zero.
Met
₩141.7B
Positive operating cash flow
Whether cash flow from operations is above zero.
Met
₩124.1B
Return on assets up
Whether net income over beginning total assets rose from the prior year.
Met
23.7% → 34.6%
Operating cash flow exceeds net income
Whether operating cash flow is greater than net income.
Not met
₩124.1B vs ₩141.7B
Liabilities-to-assets ratio down
Whether total liabilities as a share of total assets fell from the prior year.
Not met
33.0% → 35.0%
Current ratio up
Whether current assets over current liabilities rose from the prior year.
Met
163.9% → 200.6%
Shares outstanding not increased
Whether common shares issued did not increase from the prior year. Increases from bonus issues and stock dividends are also counted.
Not computable

Not computed — share count data is unavailable

Operating margin up
Whether operating income over revenue rose from the prior year.
Met
24.7% → 49.5%
Asset turnover up
Whether revenue over beginning total assets rose from the prior year.
Met
0.40x → 0.53x

A record of facts determined by fixed rules from the financial statements in the latest annual report. Not used in grading, and not a buy or sell signal. Source filing: annual report (consolidated) — view original ↗

Grade change history

Jul 23, 2026A

Methodology version change (v2.0 applied)

Jul 15, 2026AVersion v1

First calculation

Grade changes are a factual record produced from public data by a fixed formula; they do not signal future changes.

Recent filings for this stock

Last 120 days · monitored filing types only
Periodic report filedAug 14, 2026Source ↗
Periodic report filedMay 15, 2026Source ↗

View in the filings calendar →